Is TXG Worth Buying in 2026?

10x Genomics, Inc. Class A Common Stock

STOCK LABORATORY ANALYTICAL INSTRUMENTS Updated 2026-07-26

Here’s whether 10x Genomics, Inc. Class A Common Stock (TXG) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+16.18% over 10 days); RSI 64 — healthy momentum range; strong 1-year return of +237.0%; 3-month momentum positive (+109.6%). Currently 6.5% off its 52-week high. Score: +7/7.

Ready to act on this? 📈 Trade on Webull

TXG is in a confirmed uptrend, trading above both its 50-day ($34.02) and 200-day ($22.47) moving averages. An RSI of 63.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +237.0% compares to +16.5% for SPY (beat the market by 220.5%).

$10,000 invested 1 year ago → $33,700 today
vs. S&P 500 (SPY) — same period beat market by 220.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($22.47)
Above 50-day MA ($34.02)
RSI(14) neutral zone (30–70) — currently 63.6
Positive return (+237.0%)
Within 10% of period high (−6.5%)
Period Range $46.27
$11.16 $49.50
RSI (14) 63.6
0 · OversoldOverbought · 100

Key Metrics

Price$46.27
Period Return+237.0%
Period High$49.50
Period Low$11.16
Drawdown−6.5%
MA-50$34.02
MA-200$22.47
RSI (14)63.6
Avg Volume (30d)3.3M
vs. SPYbeat by 220.5%
Return Rank#41 of 999

Trade TXG

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers